Search results for "Overactive bladder"

showing 10 items of 36 documents

Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results

2016

To evaluate the role of vaginal fractional CO2 laser treatment in the relief of Overactive Bladder (OAB) symptoms in post-menopausal women.Post-menopausal women who complained of one or more symptoms related to vulvo-vaginal atrophy (VVA), who experienced symptoms of OAB and who underwent vaginal treatment with fractional CO2 laser were enrolled in the study. At baseline (T0) and 30 days post-treatment T1), vaginal status (using Vaginal Health Index - VHI), subjective intensity of VVA symptoms (using a visual analog scale - VAS) and micturition diary were evaluated. OAB symptoms were also assessed using a validated questionnaire.Thirty patients were enrolled. A statistically significant imp…

CO2 laserUrinary Bladder OveractiveOveractive bladderSocio-culturalePostmenopauseAdministration IntravaginalTreatment OutcomeLasers GasQuality of LifeCO2 laser Overactive bladder Menopause Vulvo-vaginal atrophy.HumansFemaleMenopauseVulvo-vaginal atrophyCO2 laser Overactive bladder Menopause Vulvo-vaginal atrophy
researchProduct

Therapeutic Modulation of Urinary Bladder Function: Multiple Targets at Multiple Levels

2015

Storage dysfunction of the urinary bladder, specifically overactive bladder syndrome, is a condition that occurs frequently in the general population. Historically, pathophysiological and treatment concepts related to overactive bladder have focused on smooth muscle cells. Although these are the central effector, numerous anatomic structures are involved in their regulation, including the urothelium, afferent and efferent nerves, and the central nervous system. Each of these structures involves receptors for—and the urothelium itself also releases—many mediators. Moreover, hypoperfusion, hypertrophy, and fibrosis can affect bladder function. Established treatments such as muscarinic antago…

Central Nervous Systemmedicine.medical_specialtyUrinary BladderPopulationCentral nervous systemMuscarinic Antagonistsurologic and male genital diseasesToxicologyBioinformaticsMuscle hypertrophyNeurons EfferentFibrosisInternal medicinemedicineAnimalsHumansNeurons AfferentUrotheliumeducationPharmacologyeducation.field_of_studyUrinary bladderbusiness.industryUrinary Bladder DiseasesMuscle SmoothAdrenergic beta-AgonistsHyperplasiamedicine.diseasefemale genital diseases and pregnancy complicationsUrodynamicsTreatment OutcomeEndocrinologymedicine.anatomical_structureOveractive bladderAdrenergic alpha-1 Receptor AntagonistsUrological AgentsUrotheliumbusinessSignal TransductionAnnual Review of Pharmacology and Toxicology
researchProduct

Authors' response to Hermann et al. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of mar…

2012

Hermann et al. [1] suggest that minimum quality criteria are needed to communicate unexpected drug safety findings from randomized clinical trials and imply that our report on unexpected frequent hepatotoxicity in patients receiving flupirtine for the treatment of overactive bladder syndrome [2] does not meet such criteria. As the brief report format of our paper did not allow an extensive description of trial details, we welcome this opportunity to shed more light on the matter.

PharmacologyDrugmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectOveractive bladder syndromelaw.inventionSurgeryRandomized controlled triallawMarketed productsmedicinePharmacology (medical)Quality (business)In patientIntensive care medicinebusinessmedia_commonBritish Journal of Clinical Pharmacology
researchProduct

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

2001

Objective To determine the prevalence of chronic and debilitating symptoms of the overactive bladder, defined here as the presence of chronic frequency, urgency and urge incontinence (either alone or in any combination), and presumed to be caused by involuntary detrusor contractions. Subjects and methods Data were collected using a population-based survey (conducted by telephone or direct interview) of men and women aged  40 years, selected from the general population in France, Germany, Italy, Spain, Sweden and the United Kingdom, using a random stratified approach. The main outcome measures were: prevalence of urinary frequency (> 8 micturitions/24 h), urgency and urge incontinence; the p…

Gynecologymedicine.medical_specialtyeducation.field_of_studySolifenacinUrinary urgencyTrospium chloridebusiness.industryUrologyPopulationUrinary incontinencemedicine.diseaseThe Overactive Bladder QuestionnaireOveractive bladderInternal medicinemedicinePropiverinemedicine.symptomeducationbusinessmedicine.drugBJU International
researchProduct

Ice water test in multiple sclerosis: A pilot trial.

2018

OBJECTIVES To investigate the significance of the ice water test in patients with multiple sclerosis and to evaluate a novel ice water test nomogram in a large patient cohort. METHODS A total of 201 ice water tests of patients with multiple sclerosis were retrospectively evaluated. Incontinence episodes in 24 h and sex were correlated with the ice water test. Furthermore, an ice water test nomogram was developed in order to categorize the detrusor overactivity in severity degrees. Descriptive statistics were carried out for population characteristics. Correlations of categorical variables were calculated by the χ2 -test. The independent t-test was carried out for correlations of continuous …

AdultMalemedicine.medical_specialtyMultiple SclerosisUrologyPopulation030232 urology & nephrologyUrologyPilot Projectsurologic and male genital diseases03 medical and health sciences0302 clinical medicinemedicineHumansUrinary Bladder NeurogeniceducationFalse Negative ReactionsNeurogenic bladder dysfunctionRetrospective Studieseducation.field_of_study030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryUrinary Bladder OveractiveMultiple sclerosisIceCystometryNomogramMiddle Agedmedicine.diseaseTest (assessment)NomogramsUrodynamicsOveractive bladderCohortLinear ModelsFemalebusinesshuman activitiesInternational journal of urology : official journal of the Japanese Urological Association
researchProduct

A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Resu…

2005

Abstract Objective: To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome (OAB). Methods: A prospective, double blind, double-dummy, two-arm, parallel-group, 12-week study was conducted to compare the efficacy and safety of solifenacin 5 or 10mg and tolterodine extended release (ER) 4mg once daily in OAB patients. After 4 weeks of treatment patients had the option to request a dose increase but were dummied throughout as approved product labelling only allowed an increase for those on solifenacin. Results: Solifenacin, with a flexible dosing regimen, showed greater efficacy to tolterodine in decreasing urgency episodes, inconti…

MaleSolifenacin SuccinateQuinuclidinesmedicine.medical_specialtyUrinary urgencyTolterodine TartrateUrologyPhenylpropanolamineUrologyMuscarinic AntagonistsTolterodine TartrateCresolsDouble-Blind MethodTetrahydroisoquinolinesmedicineHumansProspective StudiesBenzhydryl CompoundsAnalysis of VarianceSolifenacinbusiness.industrySolifenacin SuccinateMiddle Agedmedicine.diseaseRegimenTreatment OutcomeUrinary IncontinenceTolerabilityOveractive bladderFemaleTolterodinemedicine.symptombusinessmedicine.drugEuropean Urology
researchProduct

Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive blad…

2004

OBJECTIVE To assess the pharmacokinetics of a controlled-release formulation of oxybutynin (OROS®-O, ALZA Corp., Mountain View, CA) at different dosages, compared with immediate-release oxybutynin (IR-O), and to determine the pharmacodynamic properties in the severity-dependent reduction of urge urinary incontinence (UUI). PATIENTS AND METHODS In all, 105 patients were enrolled in this multicentre, randomized, double-blind study. Individual dose titration was used to assess the minimum effective, maximum tolerated or maximum allowed dose of either OROS-O or IR-O. Blood samples were collected during maintenance therapy with frequent sampling to analyse for R-oxybutynin and R-desethyloxybutyn…

MaleDoseUrologyUrinary incontinenceDouble-Blind MethodPharmacokineticsMaintenance therapymedicineHumansDosingOxybutyninDose-Response Relationship Drugbusiness.industryMiddle Agedmedicine.diseaseUrinary IncontinenceOveractive bladderDelayed-Action PreparationsAnesthesiaPharmacodynamicsMandelic AcidsFemaleCholinesterase Inhibitorsmedicine.symptombusinessmedicine.drugBJU International
researchProduct

Pharmacotherapy of female urinary incontinence

2005

Urinary incontinence is a major clinical problem and a significant cause of disability and dependency in older adults. Overall, the prevalence of urinary incontinence approaches 55% among women aged over 55 years. The past few years have seen significant advances in the pharmacotherapy of overactive bladder and stress incontinence. The review examines the evidence regarding their benefits and side-effects.

medicine.medical_specialtyStress incontinencebusiness.industryHealth StatusUrinary Incontinence StressAnti-Infective Agents UrinaryUrologyObstetrics and GynecologyEstrogensUrinary incontinenceMuscarinic AntagonistsMiddle Agedmedicine.diseaseAdrenergic AgonistsCholinergic AntagonistsPharmacotherapyOveractive bladderInternal medicineQuality of LifeHumansWomen's HealthMedicineFemalemedicine.symptombusinessBritish Menopause Society Journal
researchProduct

Prevalence of Levator Ani Defects in Urogynecological Patients

2016

Introduction: Defects of the levator ani muscle complex could represent a pathophysiological link between vaginal birth trauma and urogynecological symptoms many years later. The aim of our study was to determine the prevalence of levator ani muscle defects using 3D or 4D ultrasound and palpation in urogynecological patients. Material and Methods: Urogynecological patients were retrospectively investigated using 3D or 4D ultrasound. Clinical examination consisted of palpation and 3D or 4D imaging of the levator ani muscle. Results: A total of 319 women were included in the analysis. Mean age was 64.9 years, average parity was 2.1. Stress incontinence was present in 50.8 %, overactive bladde…

GynecologyStress incontinencemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryUltrasoundObstetrics and GynecologyUterine prolapsePhysical examinationUrinary incontinencemedicine.diseasePalpationLevator aniOveractive bladderMaternity and MidwiferyMedicinemedicine.symptombusinessGeburtshilfe und Frauenheilkunde
researchProduct

Does concomitant diabetes affect treatment responses in overactive bladder patients?

2013

Summary Aims To compare the efficacy and tolerability of a muscarinic receptor antagonist, darifenacin, in the treatment of overactive bladder (OAB) patients with concomitant diabetes as compared with those without comorbidities. Methods Post hoc exploratory analysis of a published, large, non-interventional study in OAB patients treated with darifenacin including 532 diabetics and 1315 controls. Associations of diabetes with treatment responses were evaluated by multiple regression models. Results Diabetics (largely type 2 patients) and controls differed in baseline age, body weight, duration of OAB symptoms and presence of comedications. However, they exhibited similar OAB symptom episode…

Malemedicine.medical_specialtyPyrrolidinesMuscarinic Antagonistsurologic and male genital diseasesAffect (psychology)Diabetes ComplicationsDiabetes mellitusInternal medicineMuscarinic acetylcholine receptorDarifenacinMedicineHumansBenzofuransDose-Response Relationship Drugbusiness.industryUrinary Bladder OveractiveAntagonistUrinary Bladder DiseasesGeneral MedicineMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsEndocrinologyTreatment OutcomeUrinary IncontinenceTolerabilityOveractive bladderConcomitantRegression AnalysisFemaleNocturiabusinessmedicine.drugInternational journal of clinical practice
researchProduct